One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 1months
-
http://medilib.ir
- Duration of Time : 31 Day
Price : 100$- Special Price : 50$
Secondary Mitral Regurgitation Trajectories and Prognosis With Intensification of Guideline-Directed Medical Therapy in Heart Failure
doi : 10.1016/j.jchf.2026.103001
Volume 14, Issue 7, July 2026, 103001
Pharmacologic Therapies for HFrEF Reduce Secondary Mitral Regurgitation: Is It Enough?
doi : 10.1016/j.jchf.2026.103178
Volume 14, Issue 7, July 2026, 103178
Socioeconomic Correlates of Incident Heart Failure and Consequent Mortality: The All of Us Program
doi : 10.1016/j.jchf.2026.103012
Volume 14, Issue 7, July 2026, 103012
Persistent Disparities in Heart Failure: Looking Under the Hood of Social Determinants of Health, Adversity, and Biology
doi : 10.1016/j.jchf.2026.103064
Volume 14, Issue 7, July 2026, 103064
Diuretic Resistance Risk and the Efficacy of Natriuresis-Guided Diuretic Therapy in Acute Heart Failure: Post Hoc Analysis From the PUSH-AHF Trial
doi : 10.1016/j.jchf.2026.103017
Volume 14, Issue 7, July 2026, 103017
Diuretic Resistance in Acute Heart Failure: Population-Level Prediction and Patient-Level Measurement
doi : 10.1016/j.jchf.2026.103156
Volume 14, Issue 7, July 2026, 103156
Association Between Hospital Tier and Cardiogenic Shock Outcomes in the United States
doi : 10.1016/j.jchf.2026.103100
Volume 14, Issue 7, July 2026, 103100
Deliberate Regionalization Without Reflexive Centralization: Designing Models of Cardiogenic Shock Care
doi : 10.1016/j.jchf.2026.103175
Volume 14, Issue 7, July 2026, 103175
Donor-Derived Cell-Free DNA as a Prognostic Biomarker After Heart Transplantation: The DEFINE-HT Study
doi : 10.1016/j.jchf.2026.103152
Volume 14, Issue 7, July 2026, 103152
Bucking Conventional Wisdom: The Experience of Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy
doi : 10.1016/j.jchf.2026.102996
Volume 14, Issue 7, July 2026, 102996
Using Days Alive and Out of Hospital as the Study Endpoint in Cardiovascular Heart Failure Clinical Trials
doi : 10.1016/j.jchf.2026.103013
Volume 14, Issue 7, July 2026, 103013
Unique Proteomic Signatures in Human Anthracycline-Induced Dilated Cardiomyopathy
doi : 10.1016/j.jchf.2026.102940
Volume 14, Issue 7, July 2026, 102940
Heart Failure Hospitalizations After the Adoption of State Telehealth Coverage Parity Laws
doi : 10.1016/j.jchf.2026.102942
Volume 14, Issue 7, July 2026, 102942
Residual Risk Despite Quadruple Medical Therapy for Men vs Women Hospitalized for Heart Failure With Reduced Ejection Fraction
doi : 10.1016/j.jchf.2026.102939
Volume 14, Issue 7, July 2026, 102939
Disrupted Sleep Architecture Preceding Incident Heart Failure: A Proof-of-Concept Study With Consumer Wearable Devices
doi : 10.1016/j.jchf.2026.102991
Volume 14, Issue 7, July 2026, 102991
Effects of Finerenone on Heart Failure Outcomes According to Baseline Heart Failure Risk in Chronic Kidney Disease and Type 2 Diabetes
doi : 10.1016/j.jchf.2026.103006
Volume 14, Issue 7, July 2026, 103006
Frailty Redefines Risk Across the Weight Spectrum in Heart Failure
doi : 10.1016/j.jchf.2026.103005
Volume 14, Issue 7, July 2026, 103005
The Seaport Criteria: A New Histologic Standard to Diagnose Myocarditis
doi : 10.1016/j.jchf.2026.103007
Volume 14, Issue 7, July 2026, 103007
Natriuretic Peptide-Based Screening for Heart Failure Among Adults With Diabetes: A Multicenter U.S. Experience
doi : 10.1016/j.jchf.2026.103010
Volume 14, Issue 7, July 2026, 103010
